These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11120962)

  • 1. Effect of dosing schedule on pharmacokinetics of alpha interferon and anti-alpha interferon neutralizing antibody in mice.
    Wang DS; Ohdo S; Koyanagi S; Takane H; Aramaki H; Yukawa E; Higuchi S
    Antimicrob Agents Chemother; 2001 Jan; 45(1):176-80. PubMed ID: 11120962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basis for dosing time-dependent changes in the antiviral activity of interferon-alpha in mice.
    Ohdo S; Wang DS; Koyanagi S; Takane H; Inoue K; Aramaki H; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2000 Aug; 294(2):488-93. PubMed ID: 10900223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.
    Osborn BL; Olsen HS; Nardelli B; Murray JH; Zhou JX; Garcia A; Moody G; Zaritskaya LS; Sung C
    J Pharmacol Exp Ther; 2002 Nov; 303(2):540-8. PubMed ID: 12388634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronopharmacological study of interferon-alpha in mice.
    Koyanagi S; Ohdo S; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 1997 Oct; 283(1):259-64. PubMed ID: 9336331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between 24-hour rhythm in antiviral effect of interferon-beta and interferon-alpha/beta receptor expression in mice.
    Takane H; Ohdo S; Baba R; Koyanagi S; Yukawa E; Higuchi S
    Jpn J Pharmacol; 2002 Dec; 90(4):304-12. PubMed ID: 12501006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of natural human IFN-alpha in hemodialysis patients.
    Gotoh A; Hara I; Fujisawa M; Okada H; Arakawa S; Kudo S; Obe T; Maruyama S; Sakai R; Kamidono S
    J Interferon Cytokine Res; 1999 Oct; 19(10):1117-23. PubMed ID: 10547151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronopharmacology of antitumor effect induced by interferon-beta in tumor-bearing mice.
    Takane H; Ohdo S; Yamada T; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2000 Aug; 294(2):746-52. PubMed ID: 10900256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of interferon alpha neutralizing antibodies on the therapeutic effectiveness in patients with chronic viral hepatitis].
    Tong F; Tang Y; Bai J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):345-7. PubMed ID: 12759973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
    Oberg K; Alm GV
    J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
    Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application.
    King M; Kumar P; Michel D; Batta R; Foldvari M
    Eur J Pharm Biopharm; 2013 Aug; 84(3):532-9. PubMed ID: 23500117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.
    Milella M; Antonelli G; Santantonio T; Giannelli G; Currenti M; Monno L; Turriziani O; Pastore G; Dianzani F
    Hepatogastroenterology; 1995 Jul; 42(3):201-4. PubMed ID: 7590565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
    Spiegel RJ; Jacobs SL; Treuhaft MW
    J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing schedule-dependent change in the disruptive effects of interferon-alpha on the circadian clock function.
    Shinohara A; Koyanagi S; Hamdan AM; Matsunaga N; Aramaki H; Ohdo S
    Life Sci; 2008 Oct; 83(15-16):574-80. PubMed ID: 18775731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
    Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
    Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs.
    Yuan L; Wang J; Shen WC
    J Control Release; 2008 Jul; 129(1):11-7. PubMed ID: 18448186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian rhythm of fever induced by interferon-alpha in mice.
    Ohdo S; Koyanagi S; Yukawa E; Higuchi S
    Life Sci; 1997; 61(8):PL95-100. PubMed ID: 9275015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a.
    Ross C; Engler CB; Sander B; Bendtzen K
    J Interferon Cytokine Res; 2002 Apr; 22(4):421-6. PubMed ID: 12034024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium Phosphate Particles as Pulmonary Delivery System for Interferon-α in Mice.
    Morçöl T; Weidner JM; Mehta A; Bell SJD; Block T
    AAPS PharmSciTech; 2018 Jan; 19(1):395-412. PubMed ID: 28752471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.